In re Omeprazole Patent Litigation, No. 10-1414 (Fed. Cir. Mar. 8, 2011)

NOTE: This disposition is nonprecedential.

United States Court of Appeals

for the Federal Circuit

IN RE OMEPRAZOLE PATENT LITIGATION

ASTRAZENECA AB, AKTIEBOLAGET HASSLE,

KBI-E, INC., KBI, INC., AND ASTRAZENECA LP,

Plaintiffs-Appellees,

v.

MYLAN LABORATORIES INC. (now known as Mylan Inc.), MYLAN PHARMACEUTICALS INC., LABORATORIOS DR. ESTEVE, S.A. and ESTEVE

QUIMICA, S.A.,

Defendants-Appellants.

2010-1414

Appeal from the United States District Court for the Southern District of New York in Nos. 00-CV-6749, 03-CV-6057, M-21-81, and MDL no. 1291, Judge Barbara S. Jones.

JUDGMENT

ERROL B. TAYLOR, Milbank, Tweed, Hadley & McCloy LLP, of New York, New York, argued for plaintiffs-appellees. With him on the brief were FREDRICK M. ZULLOW, JOHN M. GRIEM, JR., and CHRISTOPHER J. GASPAR.

2JAMES H. WALLACE, JR., Wiley Rein, LLP, of Washington, DC, argued for defendants-appellants. With him on the brief were MARK A. PACELLA and BRIAN H. PANDYA.

THIS CAUSE having been heard and considered, it is ORDERED and ADJUDGED: